Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AAVantgarde Bio

AAVantgarde announces 2 presentations at ARVO 2025 annual meeting: LUCE-1 clinical trial data from Usher 1B program & NHP GLP data from Stargardt disease program
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B at FLORetina 2024
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde announces 3 oral presentations at ESGCT 2024 annual meeting
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
From AAVantgarde Bio
Via GlobeNewswire
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
From AAVantgarde Bio
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.